Achaogen (a-KAY-o-jen) develops small molecule therapeutics to treat multi-drug resistant bacterial infections, a serious unmet medical need causing hundreds of thousands of deaths worldwide each year. Achaogen is developing next-generation aminoglycosides: “neoglycosides”— a designation that reflects their lineage and conveys their novelty.  Achaogen’s lead neoglycosides display broad-spectrum activity against many resistant bacteria that cause systemic infections, including K. pneumoniae, E. coli and MRSA.
Our world-class team has led or participated in the development of several approved and/or late-stage antibacterial compounds, and our scientific advisors include U.S. and European thought leaders in antimicrobial resistance and drug development.  We focus these resources on the tasks of compound discovery, lead optimization, and early-stage clinical trials, while leveraging external resources worldwide for screening and hit generation and for later-stage clinical work.  This maximizes our capital efficiency, minimizing infrastructure costs while mitigating the risks and costs of late phase trials.

BioAMPS International, LLC is an emerging life science company focused on the discovery, development and commercialization of proprietary antimicrobial peptide (AMPs) therapeutic solutions for the treatment of systemic infectious diseases, including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant gram-negative and gram-positive bacteria.